Application of novel tyrosine kinase inhibitor-anlotinib in osteosarcoma
A technology of osteosarcoma and tinib pharmacy, which is applied in the field of medicine to achieve the effect of enhancing the killing effect
Active Publication Date: 2018-05-01
CHIA TAI TIANQING PHARMA GRP CO LTD
View PDF4 Cites 14 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
But there is no report about the application of anlotinib in osteosarcoma
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0026] 1. Materials and Methods
[0027] 1.1 Materials Human osteosarcoma cell lines 143B, U2OS, MG63 and SJSA were purchased from the American Type Culture Collection (ATCC). Anlotinib (a new type of tyrosine kinase inhibitor) is derived from Chia Tai Tianqing Pharmaceutical Group Co., Ltd., dissolved in dimethyl sulfoxide, configured as a working mother solution of 16mMol / L, and placed in a -20°C Store in the refrigerator for later use, and adjust to the required concentration with DMEM serum culture medium before use.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
The invention relates to novel application of anlotinib and belongs to the technical field of medicine, namely effects of anlotinib in inhibition of growth and metastasis of osteosarcoma. The application disclosed by the invention has the advantages that the effect of the anlotinib for inhibiting growth and metastasis of osteosarcoma is discovered for the first time. The anlotinib is capable of obviously inhibiting the growth of osteosarcoma cell lines 143B, U2OS, MG63 and SJSA, inducing cycle arrest of the osteosarcoma and inhibiting migration and invasiveness of the osteosarcoma cell lines.The anlotinib is first discovered to be capable of enhancing a killing effect of chemotherapeutic cis-platinum on osteosarcoma cells.
Description
technical field [0001] The invention relates to the technical field of medicines, in particular to the application of anlotinib in osteosarcoma. Background technique [0002] Anlotinib is a small-molecule multi-target tyrosine kinase inhibitor developed by my country with independent intellectual property rights. Its compound patent publication number is WO2008 / 112407. It obtained clinical approval in 2011 and entered phase I clinical trials Completed in 2013, clinical trials of Anlotinib for various cancers are underway, including non-small cell lung cancer, soft tissue sarcoma, gastric cancer, colorectal cancer, medullary thyroid cancer, differentiated thyroid cancer, esophageal squamous cell carcinoma, etc. [0003] International Publication No.: WO2008 / 112407 and Chinese Patent No.: ZL200880007358.X patent documents disclose the inhibitory activity of anlotinib on colon cancer, non-small cell lung cancer, liver cancer and breast cancer. But there is no report about the a...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4709A61P35/00
CPCA61K31/4709A61K33/243A61P35/00A61P35/04A61K2300/00
Inventor 华莹奇王刚阳蔡郑东王卓莹张涛汪红胜孙梦熊
Owner CHIA TAI TIANQING PHARMA GRP CO LTD
PatSnap Eureka turns technology decisions into work you can execute. Powered by our Innovation Knowledge Graph, it runs expert workflows across engineering, life sciences, materials and intellectual property. Get your review-ready output in minutes.
